Trial Profile
A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Alisertib (Primary) ; Bortezomib (Primary) ; Rituximab
- Indications B-cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 04 Dec 2018 Results assessing safety and efficacy of Alisertib in combination with bortezomib and rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 16 Feb 2018 Planned primary completion date changed from 30 Dec 2017 to 31 Mar 2019.
- 16 Feb 2018 Status changed from recruiting to active, no longer recruiting.